Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse
Version of Record online: 21 OCT 2010
© 2010 The Authors. Journal of Pineal Research © 2010 John Wiley & Sons A/S
Journal of Pineal Research
Volume 50, Issue 2, pages 97–109, March 2011
How to Cite
Singhal, N. K., Srivastava, G., Patel, D. K., Jain, S. K. and Singh, M. P. (2011), Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse. Journal of Pineal Research, 50: 97–109. doi: 10.1111/j.1600-079X.2010.00819.x
- Issue online: 11 FEB 2011
- Version of Record online: 21 OCT 2010
- Received July 12, 2010; accepted September 8, 2010.
- Parkinson’s disease;
Abstract: Oxidative stress is reported as one of the most widely accepted mechanisms of maneb (MB)- and paraquat (PQ)-induced nigrostriatal dopaminergic neurodegeneration leading to the Parkinson’s disease (PD) phenotype. The study investigated the effects of silymarin, an antioxidant of plant origin, and melatonin, an indoleamine produced in all species, in MB- and PQ-induced mouse model of PD. The mice were treated intraperitoneally daily with silymarin (40 mg/kg) or melatonin (30 mg/kg) along with respective controls for 9 wk. Subsets of these animals were also treated with MB (30 mg/kg) and PQ (10 mg/kg), twice a week, for 9 wk, 2 hr after silymarin/melatonin treatment. Locomotor activities along with striatal dopamine content, tyrosine hydroxylase (TH) immunoreactivity, number of degenerating neurons, lipid peroxidation and nitrite content were estimated. Additionally, mRNA expression of vesicular monoamine transporter, cytochrome P-450 2E1 (CYP2E1), and glutathione-S-transferase A4-4 (GSTA4-4), catalytic activities of CYP2E1 and GSTA4-4 and protein expressions of unphosphorylated and phosphorylated p53 (p53 and P-p53), Bax and caspase 9 were measured in control and MB- and PQ-treated mice with either silymarin or melatonin treatments. Silymarin/melatonin significantly offset MB- and PQ-mediated reductions in locomotor activities, dopamine content, TH immunoreactivity, VMAT 2 mRNA expression and the expression of p53 protein. Silymarin/melatonin attenuated the increases in lipid peroxidation, number of degenerating neurons, nitrite content, mRNA expressions of cytochrome P-450 2E1 (CYP2E1) and GSTA4-4, catalytic activities of CYP2E1 and GST and P-p53, Bax and caspase 9 protein expressions. The results demonstrate that silymarin and melatonin offer nigrostriatal dopaminergic neuroprotection against MB- and PQ-induced PD by the modulation of oxidative stress and apoptotic machinery.